KRAS基因突变可以发生在多个位点，其中在非小细胞肺癌里比较常见的突变位点是G12C，胰腺癌则是G12D比较多。对于KRAS基因一直难以有好的靶向药 ...

根据最近一项大型多数据库分析的结果，携带KRAS G12C突变的结直肠癌和胰腺导管腺癌通常携带其他可能与KRAS G12C抑制剂耐药相关的遗传改变，尽管之前没有接受过这种治疗。 一项大规模多数据库分析的最新结果显示，携带KRAS G12C突变的结直肠癌和胰腺导管腺癌 ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

一直以来，KRAS都被称作“不可成药靶点”，直到KRAS G12C抑制剂的出现，才打破了这一“魔咒”。受此鼓舞，更多药企开始将目光投向KRAS的其他突变 ...

Get Instant Summarized Text (Gist) Genetic alterations co-occurring with the KRAS G12C mutation may contribute to primary resistance to KRAS G12C inhibitors in colorectal and pancreatic cancers ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic ...

In a phase 2 trial, adagrasib achieved an overall response rate of 43% in 112 patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutations who had been treated with at least one prior ...

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Science. 2016 Feb 5;351(6273):604-8. doi: 10.1126/science.aad6204. Epub ...